Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs. Naltrexone/Bupropion in Obesity
NCT04575194Phase 4Unknown
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liraglutide and naltrexone + bupropion in obesity, sponsored by National and Kapodistrian University of Athens. Primary endpoint: Blood Pressure at 6 months. Status: unknown.
02
Drugs
liraglutidenaltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04575194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575194.